



It's a Done Deal

\$5,000,000



Registered Direct

Sole Placement Agent

APRIL 2023

ROTH MKM Acted as Sole Placement Agent for RenovoRx, Inc. (Nasdaq: RNXT) in its \$5 Million Registered Direct

**For more information
please contact:**

Investment Banking

James Antonopoulos

Managing Director &
Head of Healthcare
Investment Banking
(646) 358-1906

jantonopoulos@roth.com

Aparna Beeram

Senior Vice President
(646) 358-1912

abeeram@roth.com

Equity Capital Markets

Aaron Gurewitz

President & Head of
Investment Banking
(949) 720-5703

agurewitz@roth.com

Nazan Akdeniz

COO &

Transaction Information

RenovoRx, Inc. (the "Company") (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,557,632 shares of the Company's common stock (or common stock equivalents) at a purchase price of \$3.21 per share of common stock (or common stock equivalent) in a registered direct offering priced at-the-market under Nasdaq rules. The offering closed on April 3, 2023.

In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 1,947,040 shares of common stock. The warrants have an exercise price of \$3.21 per share, will be exercisable immediately and will have a term of five and one-half years.

Roth Capital Partners acted as sole placement agent for the offering.

About RenovoRx, Inc.

Managing Director
(949) 720-5740
nakdeniz@roth.com

Lou Ellis
Managing Director
(949) 720-5739
lellis@roth.com

RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. Our mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. The proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform aims to avoid the harsh side effects typical of the current standard of care, or systemic delivery methods, thus improving patient well-being and, potentially extension of life, so more time may be enjoyed with loved ones. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and clinical use, with the goal of improving their safety, tolerance, and widening their therapeutic window by providing more targeted delivery at the location of the tumor tissue. RenovoRx's lead product candidate, RenovoGem™, is a combination of gemcitabine and its patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase III TIGeR-PaC clinical trial for the treatment of LAPC. For further information about the Company, please visit www.RenovoRx.com (Source: Company Website 3.30.23)

About ROTH MKM

ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.

[About ROTH MKM](#) | [Investment Banking](#) | [Capital Markets](#) | [Institutional Sales & Trading](#)
[Research](#) | [Corporate Services](#) | [Corporate Access & Conferences](#) | [Press Room](#)

Date of Announcement: 4.10.23

The material, information and facts discussed in this announcement other than the information regarding ROTH MKM and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2023.

Roth Capital Partners, LLC

888 San Clemente Drive, Newport Beach CA 92660 | Member SIPC/FINRA | www.roth.com

